Initiation of clinical trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy Launch of at-the-market offering of common stock for up to $6.1 million Closing on ...
Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Office The webcast at 8:30 am ET, with an accompanying presentation, will be accessible under News & Events, IR Calendar in the Investors ...
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback